This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Congenital Afibrinogenemia선천성 무피브리노젠혈증 (선천성 무피브리노겐혈증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D68.2 | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsCongenital fibrinogen deficiency, Congenital fibrinogen deficiency type I, Afibrinogenemia, factor I deficiency (complete form)
C. Adult onsetLikelihood of first presentation in adulthood low — most are diagnosed from umbilical cord bleeding in the neonatal period to early childhood or from intracranial hemorrhage in infancy. A very small number of mild phenotypes may be discovered after trauma/surgery in adulthood
1. HistoryA 100-year history from the first report by Rabe and Salomon in 1920 to the establishment of the concept of fibrinogen deficiency
2. CausesPlasma fibrinogen <0.1 g/L due to FGA, FGB, FGG gene variants
3. GeneticsFibrinogen gene cluster at 4q28, autosomal recessive
4. EpidemiologyAbout 300–500 cases reported worldwide, relatively high frequency in consanguineous populations
5. PathophysiologyParadoxical bleeding-thrombosis phenotype due to absent thrombin buffering
6. SymptomsUmbilical cord bleeding, intracranial hemorrhage, spontaneous bleeding, thrombosis; recurrent miscarriage
7. SignsPT, APTT, and TT all infinitely prolonged; fibrinogen level <0.1 g/L
8. ScreeningClauss fibrinogen assay, recognition of the infinitely prolonged TT pattern
9. DiagnosisFunctional and immunological fibrinogen quantification, FGA/FGB/FGG gene analysis
10. TreatmentFibrinogen concentrate (Riastap), FFP, fresh frozen plasma, prophylactic administration
11. PrognosisNormal life possible with appropriate prophylaxis; intracranial hemorrhage is the main cause of death
12. PreventionProphylactic fibrinogen administration, planning for prevention of obstetric complications
13. ReferencesPeyvandi F et al. (2006) J Thromb Haemost … and 11 other papers

1. History

First report by Rabe and Salomon in 1920

Congenital afibrinogenemia is one of the coagulation factor deficiency disorders with the longest history. In 1920, Rabe and Salomon of Germany first reported a boy whose blood did not clot at all from the neonatal period. This patient began with umbilical cord bleeding and experienced repeated bleeding episodes, and fibrinogen was confirmed to be completely absent from his blood. This report was the first case to clinically demonstrate the existence of fibrinogen (coagulation factor I) and its essential role in hemostasis, and it is a landmark in the history of coagulation.

Sporadic case reports followed over the next several decades, but because methods for quantifying fibrinogen were not widespread, diagnosis was often delayed or missed. In 1955, Clauss developed a functional fibrinogen assay based on the thrombin time, greatly improving diagnostic accuracy, and this method is still used as the clinical standard today.

Conceptualizing the spectrum of fibrinogen deficiency: developments in the late 20th century

In the 1960s–1980s, the concept of dividing fibrinogen disorders into quantitative deficiencies (afibrinogenemia, hypofibrinogenemia) and qualitative abnormalities (dysfibrinogenemia) was established. Dysfibrinogenemia is a condition in which fibrinogen antigen levels are normal but functional activity is reduced, and distinguishing it from congenital afibrinogenemia is clinically important.

Since the 1990s, advances in molecular genetic techniques have revealed that FGA, FGB, and FGG gene variants are the molecular basis of fibrinogen deficiency. These three genes form the fibrinogen gene cluster, all grouped within a range of about 50 kb on chromosome 4q28. In the early 2000s, as international collaborative research through the EN-RBD network progressed, the clinical spectrum and catalog of molecular variants of congenital fibrinogen deficiency were systematically established.

Recognition of the thrombosis-bleeding paradox and the multifunctionality of fibrinogen

Since the 2000s, clinical reports of thrombosis occurring in patients with afibrinogenemia have attracted attention. Research into why thrombi form in the complete absence of fibrinogen produced a new understanding that fibrinogen is not merely a coagulation substrate but plays a buffering role by adsorbing and regulating thrombin. In addition, because fibrinogen also acts as a ligand for platelet aggregation (GP IIb/IIIa receptor), it became known that platelet dysfunction also accompanies fibrinogen deficiency.

2. Causes

Variants in the fibrinogen gene cluster

The direct cause of congenital afibrinogenemia is pathogenic variants in one or more of the three fibrinogen genes (FGA, FGB, FGG). Fibrinogen is a hexameric protein synthesized in the liver, composed of two each of the Aα chain (FGA gene), Bβ chain (FGB gene), and γ chain (FGG gene). If even one chain is not synthesized, assembly and secretion of the entire hexamer are blocked, and plasma fibrinogen levels fall to below 0.1 g/L (normal 1.5–4.0 g/L).

By variant type, FGA gene variants are the most frequently reported, and among them, the FGA exon 1–2 deletion (splicing variants such as c.510+1G>T) has been identified as a founder variant in people of Iranian ancestry. FGB variants include promoter variants, and FGG variants are relatively rare. Afibrinogenemia is caused by homozygous or compound heterozygous variants.

Differentiation from congenital hypofibrinogenemia and dysfibrinogenemia

Fibrinogen deficiency is clinically classified into three types. Afibrinogenemia is complete deficiency in which plasma fibrinogen is almost undetectable, and is the most severe. Hypofibrinogenemia is partial deficiency with fibrinogen reduced to 0.1–1.5 g/L, mainly observed in heterozygous variant carriers. Dysfibrinogenemia is a qualitative abnormality in which fibrinogen antigen is normal but function is reduced; it is caused by separate missense variants, and some cases cause thrombosis. These three types are distinguished by the ratio of the Clauss assay (functional) to the immunoassay (antigen).

3. Genetics

Structure of the fibrinogen gene cluster

The three fibrinogen genes FGA, FGB, FGG all form a gene cluster concentrated within a range of about 50 kb on chromosome 4q28. The FGA gene consists of 6 exons, the FGB gene of 8 exons, and the FGG gene of 10 exons. These three genes are known to derive evolutionarily from a common ancestral gene and share amino acid sequence similarity. All three genes are expressed mainly in hepatocytes, and the three synthesized chains are assembled in the endoplasmic reticulum into the Aα₂Bβ₂γ₂ hexamer through disulfide bonds and then secreted into the plasma.

Autosomal recessive inheritance and the clinical significance of heterozygous carriers

Congenital afibrinogenemia is inherited in an autosomal recessive manner. Because variants on both alleles are required for disease, when both parents are heterozygous carriers, each pregnancy has a 25% probability of an affected child. Heterozygous carriers have fibrinogen levels around 50% of normal (hypofibrinogenemia) but usually have no bleeding symptoms. However, the bleeding risk increases when fibrinogen levels fall below the threshold (0.5–1.0 g/L) during surgery or trauma. To date, more than 200 pathogenic variants have been reported across the three genes combined, and the ISTH SSC fibrinogen subcommittee maintains a variant database.

4. General epidemiology

Extremely rare prevalence

Congenital afibrinogenemia is an extremely rare disease, with only about 300–500 cases reported worldwide to date. The exact prevalence is unknown but is estimated at roughly 1 per million. There is no sex difference (autosomal recessive), and it can occur in all ethnic groups. Clustered occurrence through consanguineous families has been reported in Iran, Pakistan, southeastern Turkey, and some Mediterranean regions.

Reports in Korea

Congenital afibrinogenemia is very rare in Korea, and only a handful of domestic cases have been reported. The disease is listed in the Korean rare disease information system and is registered and managed under the health insurance Special Copayment Reduction code V009. Most domestic patients are severe cases diagnosed from umbilical cord bleeding in the neonatal period or intracranial hemorrhage in infancy, and cases first diagnosed with a mild phenotype in adulthood are very rare. In Korea, approval of fibrinogen concentrates and insurance coverage issues affect access to treatment.

5. Pathophysiology

Multiple functions of fibrinogen and the pathophysiology of deficiency

Fibrinogen is the final substrate of the coagulation cascade, cleaved by thrombin into fibrin monomers that then polymerize to form a blood clot. However, the physiological role of fibrinogen is not limited to being a coagulation substrate. As a ligand for platelet aggregation, fibrinogen binds to the GP IIb/IIIa receptor on the platelet surface and mediates platelet aggregation. Therefore, in patients with afibrinogenemia, platelet aggregation is also impaired by the absence of fibrinogen, and functional hemostasis does not occur even when the platelet count is normal.

The thrombosis-bleeding paradox: loss of thrombin buffering function

The paradoxical occurrence of thrombosis in afibrinogenemia is explained by loss of the thrombin buffering role of fibrinogen. Normally, excess thrombin is 'consumed' as it binds fibrinogen to form fibrin, but without fibrinogen, thrombin is not consumed and accumulates in free form in the blood. This free thrombin promotes intravascular coagulation through other substrates (protein C, thrombomodulin), leading to thrombus formation. There is also a hypothesis that in fibrinogen deficiency, because there is no ligand to bind platelets, uncontrolled signaling in activated platelets may contribute to thrombosis.

Mechanisms of obstetric complications

Fibrinogen is also essential for placental implantation and maintenance of pregnancy. Experimental animals (fibrinogen-deficient mice) have demonstrated that fibrinogen is required to maintain pregnancy, and in humans, women with afibrinogenemia have high rates of recurrent miscarriage and placental abruption. Replacement therapy maintaining fibrinogen levels at 1.0–1.5 g/L or higher during pregnancy is necessary to maintain pregnancy.

6. Symptoms

Bleeding in the neonatal period and infancy

The most common and characteristic initial symptom of congenital afibrinogenemia is umbilical cord bleeding in the neonatal period. Persistent bleeding occurs within a few hours after the umbilical cord is ligated just after birth, and this becomes the first clue to the diagnosis. Thereafter, excessive bleeding recurs even after minor trauma such as circumcision, vaccination, or blood sampling. In infancy, spontaneous intracranial hemorrhage (ICH) can occur, which is a major cause of permanent neurological damage and death. Intracranial hemorrhage accounts for the highest proportion of deaths among untreated patients with afibrinogenemia.

Various forms of spontaneous bleeding

Spontaneous bleeding recurring through childhood and adulthood includes intramuscular hematomas, joint bleeding (hemarthrosis), epistaxis (nosebleeds), gum bleeding, and gastrointestinal bleeding. Joint bleeding is rarer than in hemophilia A but is reported in severe afibrinogenemia. Spontaneous splenic rupture has been reported extremely rarely. In female patients, menorrhagia, ovulation bleeding, and massive postpartum hemorrhage are important clinical problems.

Thrombosis: a paradoxical complication

Arterial or venous thrombosis is reported to occur in about 10–20% of patients with afibrinogenemia. Thrombosis sites vary, including deep veins (lower limbs, cerebral venous sinuses) and arteries (cerebral, mesenteric). In particular, thrombosis can occur suddenly after administration of fibrinogen concentrate, so care is needed during treatment to keep fibrinogen levels from rising too high. In obstetrics and gynecology, placental abruption may also occur together with thrombotic lesions.

7. Signs

Infinite prolongation of all clotting times in coagulation tests

The most characteristic laboratory finding of congenital afibrinogenemia is that PT, APTT, and thrombin time (TT) are all infinitely prolonged (unclottable). Because fibrinogen sits at the common final step of the coagulation cascade, fibrin formation is impossible in the extrinsic, intrinsic, and common pathways alike without fibrinogen. As a result, all coagulation tests are extremely prolonged. Functional fibrinogen measured by the Clauss method is below the detection limit (usually 0.05–0.1 g/L), and immunological fibrinogen measurement also shows minimal or undetectable levels.

Accompanying platelet dysfunction

In patients with afibrinogenemia, despite a normal platelet count, platelet function tests (e.g., platelet aggregation testing, PFA-100) show abnormal aggregation in response to ADP and collagen stimulation. This is because fibrinogen is an essential ligand for GP IIb/IIIa-mediated platelet aggregation. This platelet dysfunction is corrected after fibrinogen replacement.

8. Screening

Clinical interpretation of the pattern of prolonged clotting times

A pattern in which PT, APTT, and TT are all extremely prolonged is the first clue to afibrinogenemia. However, this pattern can also appear in DIC, severe liver disease, and high-dose heparin use. When this pattern is found in a neonate with bleeding, fibrinogen quantification should be performed immediately. If acquired causes are excluded and functional fibrinogen is below 0.1 g/L, congenital afibrinogenemia is suspected.

Comparison of functional and antigenic fibrinogen

By comparing functional fibrinogen measured by the Clauss method with fibrinogen antigen measured by immunoassay, quantitative deficiency (a-/hypofibrinogenemia) is distinguished from qualitative abnormality (dysfibrinogenemia). In afibrinogenemia, both measurements are extremely low; in dysfibrinogenemia, the antigen level is normal but the functional level is low. In hypofibrinogenemia, both measurements are proportionally reduced.

9. Diagnosis

Steps of confirmatory testing

The definitive diagnosis of congenital afibrinogenemia proceeds in the following steps. Step 1: confirm coagulation screening tests (extreme prolongation of PT, APTT, TT). Step 2: quantify functional fibrinogen by the Clauss method and antigenic fibrinogen by immunoassay. Step 3: exclude acquired causes (DIC, liver disease, heparin). Step 4: identify pathogenic variants by Sanger analysis or NGS panel testing of the FGA, FGB, and FGG genes. Step 5: determine carrier status of parents and siblings (confirm heterozygous hypofibrinogenemia).

Clinical significance of genetic analysis

Molecular genetic diagnosis provides the basis for confirmation, genetic counseling, and prenatal diagnosis. Targeted variant testing is cost-effective, especially in populations with known founder variants such as Iran and Pakistan. The fibrinogen variant database (maintained by the ISTH SSC) includes the exon 2 deletion of the Aα chain (Iranian type), various Bβ chain variants, and others. Genotype-phenotype correlation is generally good, but heterogeneity of bleeding and thrombotic phenotypes is observed even among patients with the same variant.

10. Treatment

Role of fibrinogen concentrate

The core of treatment for congenital afibrinogenemia is administration of fibrinogen concentrate. Representative currently available products are the plasma-derived fibrinogen concentrates Riastap (CSL Behring) and Haemocomplettan P (CSL Behring), and research on recombinant fibrinogen is under way in some countries. The goal for treating bleeding is to correct fibrinogen to 1.0–1.5 g/L or higher, and the goal for preoperative prophylaxis is 1.5–2.0 g/L or higher. Fresh frozen plasma (FFP) also supplies fibrinogen, but large volumes are needed, with risks of serious transfusion reactions and volume overload.

Prophylactic administration strategy

In patients with a history of intracranial hemorrhage or at high risk, prophylactic fibrinogen administration (secondary prophylaxis) is recommended. Generally, fibrinogen concentrate is given at 1–2 week intervals to maintain trough fibrinogen levels of 0.5–1.0 g/L or higher. Some specialist centers also perform primary prophylaxis (started before the first bleed). Tranexamic acid is used adjunctively for mucosal bleeding, but caution is needed with concurrent use immediately after fibrinogen concentrate administration because of the risk of thrombosis.

Obstetric management and maintenance of pregnancy

To maintain pregnancy in women with afibrinogenemia, prophylactic administration maintaining fibrinogen levels at 1.0–1.5 g/L or higher throughout pregnancy is required. Low fibrinogen levels in the first trimester carry a high risk of implantation failure or early miscarriage. At delivery, fibrinogen is maintained at 1.5–2.0 g/L or higher around surgery or delivery. A multidisciplinary team (hematology, obstetrics and gynecology, neonatology) collaboration system is essential for the safety of both mother and newborn.

11. Prognosis

Stark difference in prognosis with and without treatment

Patients receiving appropriate fibrinogen concentrate replacement therapy are protected from intracranial hemorrhage and can lead normal social lives. In contrast, in patients who are untreated or diagnosed late, the risk of neurological damage and death from recurrent intracranial hemorrhage is very high. According to EN-RBD cohort studies, the main causes of death in patients with afibrinogenemia are intracranial hemorrhage (about 30%) and thrombosis (about 20%).

Long-term complications and monitoring

Patients receiving long-term fibrinogen concentrate should be monitored for the risk of thrombosis. Because the risk of thrombosis increases with fibrinogen over-replacement, keeping the upper limit of the target fibrinogen level below 2.0 g/L is generally recommended. In addition, because fibrinogen concentrate is plasma-derived, a theoretical risk of blood-borne infection cannot be excluded, but current products undergo rigorous viral inactivation, so the practical risk is very low.

12. Prevention

Prophylactic fibrinogen administration protocol

In patients with severe afibrinogenemia at high risk of intracranial hemorrhage (especially children), periodic prophylactic administration is the core of primary prevention. The dose is individualized according to the patient's weight, baseline fibrinogen level, and target trough level. Generally, fibrinogen concentrate at 40–80 mg/kg per dose is given at 1–2 week intervals. Fibrinogen levels are measured before and after administration to confirm that the target range (trough 0.5–1.0 g/L) is maintained.

Genetic counseling and newborn screening

Genetic counseling for the parents and siblings of patients with afibrinogenemia includes carrier screening. Carriers (heterozygous hypofibrinogenemia) are usually asymptomatic, but monitoring of fibrinogen levels during surgery, trauma, and pregnancy is recommended. Prenatal diagnosis (FGA/FGB/FGG gene analysis by chorionic villus sampling or amniocentesis) is possible, and in newborns with a family history, fibrinogen measurement including coagulation screening tests immediately after birth is recommended.


13. References

  1. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost. 2006;4(7):1634–1637.
  2. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol. 1999;107(1):204–206.
  3. Rabe F, Salomon E. Über Faserstoffmangel im Blute bei einem Falle von Hämophilie. Dtsch Arch Klin Med. 1920;132:240–244.
  4. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39(6):585–595.
  5. Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost. 2016;42(4):366–374.
  6. Neerman-Arbez M, de Moerloose P, Bridel C, et al. Mutations in the fibrinogen Aalpha-chain gene account for the majority of cases of congenital afibrinogenemia. Blood. 2000;96(1):149–152.
  7. Kobayashi T, Terao T, Maki M, Ikenoue T. Diagnosis and management of acute obstetrical DIC. Semin Thromb Hemost. 2001;27(2):161–167.
  8. Trehan N, Hall DB, Chumps M. Prophylactic fibrinogen concentrate in congenital afibrinogenemia: a case series. Haemophilia. 2012;18(3):e143–e146.
  9. Manco-Johnson MJ, Dimichele D, Castaman G, et al. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost. 2009;7(11):2067–2073.
  10. Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost. 2011;9(9):1687–1704.
  11. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17(4):237–246.
  12. Acharya SS, Coughlin A, Dimichele DM. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost. 2004;2(2):248–256.